Comparative Effects of Exercise and Metformin on Glycemic Control in Prediabetic Adults
NCT ID: NCT07061496
Last Updated: 2025-07-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
NA
226 participants
INTERVENTIONAL
2025-08-10
2026-03-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Exercise Intervention Combined With Metformin in the Treatment of Type 2 Diabetes
NCT05004948
The Effects of Metformin on Self-selected Exercise Intensity, Physical Fitness and Exercise-induced AMPK-activation
NCT02951260
Effects of Exercise and Metformin on Methylglyoxal Levels in Prediabetic Individuals
NCT06603480
Optimization of Exercise Protocol for Prediabetic Population in Postprandial State
NCT06656377
Exercise Dose and Metformin for Vascular Health in Metabolic Syndrome
NCT03355469
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Exercise Group
Moderate aerobic activity (e.g., brisk walking) for 30-45 minutes/day, 5 days/week, for 12 weeks.
Moderately intense exercise
Structured moderate-intensity aerobic activity (e.g., brisk walking) for 30-45 minutes/day, 5 days/week, for 12 weeks.
Metformin Group
Participants will receive oral metformin 500 mg twice daily for 12 weeks.
MetFORMIN 500 Mg Oral Tablet
Participants will receive oral metformin 500 mg twice daily for 12 weeks.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Moderately intense exercise
Structured moderate-intensity aerobic activity (e.g., brisk walking) for 30-45 minutes/day, 5 days/week, for 12 weeks.
MetFORMIN 500 Mg Oral Tablet
Participants will receive oral metformin 500 mg twice daily for 12 weeks.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosed with prediabetes based on ADA criteria (FPG: 100-125 mg/dL or HbA1c: 5.7-6.4%)
* Stable HbA1c levels (no significant fluctuation in the last 3 months)
* Body Mass Index (BMI) less than 30 kg/m²
* Willing and able to provide written informed consent
* Willing to participate in the assigned intervention (exercise or metformin) for 12 weeks
* Residing within the community and able to attend scheduled follow-ups
Exclusion Criteria
* Diagnosis of Type 2 Diabetes Mellitus (T2DM) or use of anti-diabetic medications
* Family history of diabetes in first-degree relatives (parent or sibling)
* Known cardiovascular, renal, or hepatic disease
* Pregnancy or lactation
* Physical disability or limitation that would interfere with performing moderate-intensity exercise
* Uncontrolled hypertension (SBP ≥ 160 mmHg or DBP ≥ 100 mmHg)
* Known allergy or contraindication to metformin
* Alcohol or substance abuse
18 Years
59 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
CMH Nowshera
UNKNOWN
Umair Ali
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Umair Ali
Dr
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Umair Ali
Role: PRINCIPAL_INVESTIGATOR
CMH Nowshera
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Preventive Medicine, Combined Military Hospital Nowshera
Nowshera, , Pakistan
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CMHNSR-REF-17
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.